Voyager Therapeutics, Inc.
VYGR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -68% | 511.2% | 9.3% | – |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | 100% | 63.1% | -36.3% | -97.2% |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -98.2% | 50.6% | -96.9% | -183% |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -81.3% | 52.9% | -113.4% | -190.3% |
| EPS Diluted | -1.13 | 2.97 | -1.21 | -1.75 |
| % Growth | -138% | 345.5% | 30.9% | – |
| Operating Cash Flow | -$0 | $0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | $0 | -$0 | -$0 |